4 – Alzheimers

Although there were promising results in a phase 2 trial, patients with mild Alzheimer disease who received the drug tarenflurbil as part of a phase 3 trial did not have better outcomes on measures of cognitive decline or loss of activities of daily living compared to patients who received placebo, according to a new study.

Here is the original post:
Drug for Alzheimer’s disease does not appear to slow cognitive decline (Science Daily)

Tags: received-the, renflurbil-as-part, received-the-drug, there-were, not-have

Related posts:

1. New compound improves cognitive decline, symptoms of Alzheimer’s disease in rodents (Science Daily)
2. Test for Alzheimer’s disease predicts cognitive decline in Parkinson’s disease
3. Regular Walking May Slow Decline of Alzheimer’s
4. Neuroimaging study may pave way for effective Alzheimer’s treatments (Science Daily)
5. HIV-related memory loss linked to Alzheimer’s protein (Science Daily)

This entry was posted on Monday, December 28th, 2009 at 4:11 am and is filed under Alzheimer's Disease. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.